日本医科大学医学会雑誌
Online ISSN : 1880-2877
Print ISSN : 1349-8975
ISSN-L : 1349-8975
19 巻, 3 号
選択された号の論文の18件中1~18を表示しています
特集〔遺伝子治療 update:日本医科大学の遺伝子治療研究〕
  • 三宅 弘一
    2023 年 19 巻 3 号 p. 198
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー
  • 島田 隆
    2023 年 19 巻 3 号 p. 199-204
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    Once a dream cure for genetic diseases, gene therapy came to be considered potentially realizable with the advent of recombinant DNA technology in the 1970s. In the 1980s, viral vectors were developed, and ethical issues regarding human gene manipulation began to be addressed. In 1990, the world’s first gene therapy was launched in the United States. Since then, various gene therapies have been tried around the world, but have failed to show clear efficacy. In addition, safety problems, including a fatal accident and the development of leukemia, have occurred with gene therapy. Consequently, the once high expectations for gene therapy declined. Since the end of the 2000s, however, the efficacy of gene therapies for treatment of genetic diseases and cancer has been confirmed time and again, and expectations for gene therapy have been revived. At present, more than 20 gene therapy products have been approved, and gene therapies are now poised to become practical medicine.

  • 内田 直也
    2023 年 19 巻 3 号 p. 205-210
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    Gene therapy targeting hematopoietic stem cells (HSCs) is a promising treatment for a variety of genetic disorders, including immunodeficiency, hemoglobinopathies, congenital cytopenia, and metabolic diseases. HSCs can reconstitute peripheral blood throughout life due to their capacity for self-renewal and their hematopoietic multipotency. This makes it possible to cure genetic diseases for an entire lifetime by replacing or repairing pathogenic mutations/deletions in HSCs. Autologous HSC-targeted gene therapies entailing lentiviral gene addition as well as gene editing are currently under development. These can be widely applied to most patients, as there is no requirement for a suitable donor. Current gene addition/editing therapies are based on harvesting the patient's CD34+ HSCs, performing gene modification ex vivo, and then transplanting the modified HSCs back into the patient. The efficacy of ex vivo lentiviral HSC gene therapy has been proved in recent trials; however, the ex vivo process requires a GMP-level cell processing center and is expensive, which limits its global application. It is therefore crucial to develop in vivo HSC gene therapies, in which a therapeutic gene or gene editing tools can be delivered directly into bone marrow HSCs via systemic administration without ex vivo culture. This manuscript presents an overview of the current HSC-targeted gene therapies using lentiviral vectors.

  • 平井 幸彦
    2023 年 19 巻 3 号 p. 211-217
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    The development of gene therapy products using adeno-associated virus (AAV) vectors is progressing, and the gene therapy market is rapidly expanding. AAV shows no pathogenicity in the human body, has extremely low cytotoxicity and, unlike lentiviral and retroviral vectors, rarely integrates into chromosomes. Consequently, risk associated with AAV was thought to be low. In recent years, however, adverse events such as hepatotoxicity have become apparent as cases accumulate among laboratory animals and in clinical trials. In this paper, we present an overview of the integration of AAV vectors into the genome of infected cells, which is thought to be the cause of adverse events.

  • 宮川 世志幸
    2023 年 19 巻 3 号 p. 218-223
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    In recent years, gene and cell therapies have become widely accepted as new therapeutic modalities, and a number of gene therapy drugs have been approved. Underlying this advance are innovations in gene delivery tools, especially viral vectors, which are no longer simply gene transfer tools in basic research. Since its initial inception, all aspects of gene therapy have been dramatically improved, including their safety, functionality, and production technology. On the other hand, with use of gene therapies clinically, new safety and efficacy concerns have emerged, and gene therapy is now entering a new phase. Both preclinical and clinical data have demonstrated that simple overexpression of a therapeutic gene at a disease site through transduction by a gene delivery vector is not sufficient to ensure safety and therapeutic efficacy. Maturation of this field will require more sophisticated gene delivery vector systems and highly regulated therapeutic gene expression systems to precisely introduce these genes into target cells and express them to the appropriate degree at the appropriate time. Herpes simplex virus (HSV)-based vectors are extremely safe and functional vector systems that have the potential to meet current challenges in gene and cell therapy. This makes HSV vectors promising gene delivery vehicles for gene therapy. This chapter will focus on the current trends in the development of HSV as a delivery vector for gene therapy.

  • 三宅 紀子
    2023 年 19 巻 3 号 p. 224-228
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    Lysosomal storage diseases (LSDs) are a heterogeneous group of diseases caused by genetically determined defects in lysosomal enzymes. Specific molecular mechanisms and disease phenotypes depend on the type of storage material affected. Current treatments for LSDs include enzyme replacement therapy (ERT) and hematopoietic cell transplantation (HCT) from allogeneic healthy individuals. However, those approaches are applicable only to a limited number of LSDs and lack efficacy for some clinical conditions. Hematopoietic stem cell gene therapy (HSC-GT) incorporating lentiviral vectors has shown strong clinical efficacy when administered to patients with metachromatic leukodystrophy (MLD) and is now registered as a pharmaceutical product. More recently, HSC-GT has also shown promising results in patients with Hurler’s syndrome. Here, we report on the treatment for MLD currently being used in clinical practice and the gene therapy for MLD being studied at Nippon Medical School.

  • 松本 多絵
    2023 年 19 巻 3 号 p. 229-234
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    Hypophosphatasia (HPP) is an inherited bone disease resulting from a deficiency of tissue-nonspecific alkaline phosphatase (TNALP). It is fatal in its severe perinatal and infantile forms. Asfotase alfa (Strensiq®) is an approved enzyme replacement therapy for HPP. It's use requires injections 3-6 times per week for all of the patient's life. Therefore, although this treatment is effective, it is also burdensome. We investigated the efficacy and safety of a gene therapy drug (TNALP-D10-expressing type 8 adeno-associated virus vector: ARU-2801) administered intramuscularly to Alpl−/− mice (infantile HPP model) and non-human primates with the aim of developing a less burdensome treatment. After administration of 3.0×1011 vg/body (n=4/7) or 1.0×1012 vg/body (n=5/7) ARU-2801, treated mice maintained high plasma ALP activity and exhibited body weight gain and bone maturity similar to wild-type mice throughout their survival period, which was up to 18 months. Biodistribution of ARU-2801 was detected only in the intramuscular region on the administration side. There were no tumors or ectopic calcification detected at autopsy or histopathological examination. After administration of 1.0×1013 vg/body ARU-2801 to juvenile macaque monkeys, durable high plasma ALP levels were sustained for up to 38 weeks with no biochemical abnormalities detected in the blood. Radiological and histopathological examinations also showed no abnormality. The clinical chemistry parameters for ARU-2801-treated mice and macaques indicated that plasma ALP activity is maintained with no toxicities at levels that are potentially clinically efficacious. Thus, ARU-2801, which can be administered as a single dose, has the potential to improve the quality of life of HPP patients by eliminating the need for indefinitely repeated injections.

  • 黒田 誠司, 助川 誠
    2023 年 19 巻 3 号 p. 235-241
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    A quarter of a century has passed since the expected realization of "Conquering cancer in the 21st century" due to advances in pharmaceuticals and medical technology. However, the effectiveness of treatments for malignant tumors, especially refractory cancers, remains inadequate and is difficult to achieve with conventional treatment methods alone. For example, there are high rates of metastasis and residual recurrence following surgical treatment, while chemotherapy and radiotherapy all too quickly lead to disease resistance, and their side effects significantly reduce patients’ quality of life. Under such circumstances, gene therapy products targeting cancer are some of the most highly desired therapies worldwide. The advantages of these innovative treatments are their clear mechanism of action and clinical efficacy based on molecular pathology. Several gene therapies have been approved for hematologic tumors and have shown dramatic therapeutic effects. On the other hand, the efficacy of gene therapies against solid tumors remains limited and improving their therapeutic efficacy remains a major challenge. In this review, we report the background and current status of gene therapy for cancer. In addition, oncolytic virus therapy and CAR-T cell therapy, which have the potential to be curative and are undergoing research and development, will be introduced in detail.

  • 五十嵐 勉
    2023 年 19 巻 3 号 p. 242-246
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    In the field of ophthalmology, gene therapy has focused on hereditary retinal dystrophy, including retinitis pigmentosa. Hereditary retinal dystrophy is a group of intractable diseases for which there is currently no effective treatment, and expectations are focused on gene therapy and retinal regeneration therapy using iPS cells. In recent years, results of a number of clinical trials of gene therapies for hereditary retinal dystrophy have been reported from Europe and the United States. Since 2017, gene therapy drugs for Leber congenital amaurosis have been approved after being found to be safe and therapeutically efficacious. In this article, we will discuss the current state of gene therapy for retinitis pigmentosa and the use of adeno-associated virus (AAV) vectors in gene therapy.

橘桜だより
グラビア
綜説
  • 櫻澤 信行
    2023 年 19 巻 3 号 p. 254-262
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    Gastric cancer used to be the leading cause of cancer mortality in Japan, but the rate has been decreasing in recent years due to declining numbers of Helicobacter pylori infections. However, even now, it is still a major cancer in this country, ranking third in both the number of cases (2019) and number of deaths (2020). Treatment in the preoperative stages has improved thanks to the increased accuracy of preoperative examinations such as endoscopy and computed tomography, with treatment decisions based on prognosis in consideration of the stage of the disease, and the degree of invasiveness the patient will be able to tolerate. Endoscopic resection is indicated for mucosal cancer without lymph node metastasis (stage IA), while anticancer agents are used for stage IV patients with peritoneal dissemination and other cases where radical resection is impossible. Otherwise, surgery is the main treatment. In the past, open surgery dominated, but in recent years, minimally invasive laparoscopic surgery that creates smaller wounds has become widespread. Recently, robotic surgery with such functions as camera shake prevention has been developed, and this enables even more precise surgery. With reference to our own research, this article outlines the historical evolution of gastric cancer surgery and the current status of minimally invasive surgery.

症例報告
  • 林 暢彦, 桐山 智成, 小林 理佳, 中込 哲平, 楊 菜洋, 汲田 伸一郎, 木村 剛, 近藤 幸尋
    2023 年 19 巻 3 号 p. 263-268
    発行日: 2023/08/31
    公開日: 2023/09/16
    ジャーナル フリー

    Chronic expanding hematomas (CEH) are hematomas that continue to expand at least one month after onset. CEH often occur in the thoracic cavity or in the extremities secondary to trauma, surgery, anticoagulation therapy, or bleeding disorders. Few studies have reported CEH in retroperitoneal organs such as the adrenal glands and lesions without an apparent etiology. An 80-year-old woman was referred to our hospital for evaluation of a retroperitoneal tumor that was incidentally detected on ultrasonography. Computed tomography and magnetic resonance imaging showed a large left retroperitoneal mass (14 cm in diameter) with gradual peripheral enhancement and a suspected hemorrhagic component within the lesion. Parametric imaging using positron emission tomography (PET) showed mild accumulation of the tracer at the margins of the mass on the conventional standard uptake value images, relatively low accumulation on the slope images, and slightly higher accumulation on intercept images. Postoperative histopathological examination of the resected specimen revealed a mass that was encapsulated with fibrous tissue and primarily consisted of organized clots without evidence of tumor cells; the mass was diagnosed as an idiopathic CEH of the adrenal glands. The margins of the mass showed few inflammatory cell infiltrates consistent with the findings of parametric imaging, which appeared to accurately reflect the dynamics of fluorodeoxyglucose (FDG) in the body. PET parametric imaging can separately assess the metabolism and distribution of FDG in vivo and may be useful to determine the etiology and diagnosis of CEH.

話題
JNMSのページ
特集〔医療における AI の可能性〕第 32 回公開「シンポジウム」
feedback
Top